Abstract
There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.
| Original language | English |
|---|---|
| Journal | MedGenMed Medscape General Medicine |
| Volume | 6 |
| Issue number | 3 SUPPL. |
| State | Published - 2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Advances in diabetes for the millennium : Drug therapy of type 2 diabetes CME. / Rendell, Marc.
In: MedGenMed Medscape General Medicine, Vol. 6, No. 3 SUPPL., 2004.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Advances in diabetes for the millennium
T2 - Drug therapy of type 2 diabetes CME
AU - Rendell, Marc
PY - 2004
Y1 - 2004
N2 - There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.
AB - There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.
UR - http://www.scopus.com/inward/record.url?scp=27444433718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27444433718&partnerID=8YFLogxK
M3 - Article
C2 - 15647714
AN - SCOPUS:27444433718
VL - 6
JO - MedGenMed Medscape General Medicine
JF - MedGenMed Medscape General Medicine
SN - 1531-0132
IS - 3 SUPPL.
ER -